MRI Compared to PET/CT for Staging and Treatment Response in Lymphoma

Guangxi Medical University66 enrolled

Overview

The lymph nodes or masses,positron emission tomography/computed tomography (PET/CT) standardized uptake values(SUV) results, whole body magnetic resonance imaging(MRI) intravoxel incoherent motion(IVIM) sequence D, D\*, f values and MRI volumes of lymphoma patients were compared before and after the chemotherapy in this project prospectively to provide data for evaluating the dependency and differences of PET/CT and whole body MRI in lymphoma staging and therapeutic evaluation. Long-term therapeutic effect indexes obtained in follow-up visits of patients such as Overall Survival(OS), Progression Free Survival (PFS) etc. were used to evaluate the diagnostic sensitivity and differences of MRI and PET/CT. The research could provide a new method of nonionizing radiation iconography for physicians to give appropriate treatments and predict prognosis.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Lymphoma

Interventions

MRI was performed on a 3 Tesla system (GE Discovery 750W). A single-shot,echo-planar imaging-based, spectral adiabatic inversion recovery DWI sequence was obtained with b values of 0,30,50,80,100,150,200,400,600,800 and 1,000.

positron emission tomography/computed tomographyDEVICE

18F-FDG-PET/CT was performed using a multidetector PET/CT system (GE Discovery ST16). Patients fasted for 6 hours before imaging.

fludeoxyglucose F 18RADIATION

Patients fasted for 6 h before receiving FDG intravenously. A dose of 5.18-7.4 MBq/kg was used.

Eligibility

Sex: ALLMin age: 8 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Lymphoma subtypes were diagnosed on the basis of tissue samples obtained by biopsy or surgery according to the criteria outlined in the current World Health Organization (WHO) classification of hematologic and lymphoid malignancies, by a reference pathologist. * Patients who gave written informed consent were referred for DWI-MRI and 18F-FDG-PET/CT. * Stable physical medical conditions (patients conscious and comfortable, scheduled for an elective diagnostic imaging). Exclusion Criteria: * Pregnancy, general contraindications to MRI, and therapeutic interventions between DWI-MRI and 18F-FDG-PET/CT were used.

Locations (1)

Affiliated Tumor Hospital，Guangxi Medical University

Nanning, China

RECRUITING

Outcomes

Primary Outcomes

18F-FDG uptake in lymphomas with PET/CT

Different 18F-FDG uptake values in lymphoma tissue (e.g. SUVmax, SUVmean, binding potential) will be measured and correlated with immunohistochemically determined somatostatin receptor status, lymphoma aggressiveness and tissue biomarkers

Time frame: Within 30 days prior to start of chemotherapy

Agreement between DWI-MRI and 18F-FDG PET/CT at diagnosis

Region based agreement (%; kappa value) of DWI-MRI with 18F-FDG PET/CT at diagnosis.

Time frame: Within 30 days prior to start of chemotherapy

Agreement between DWI-MRI and 18F-FDG PET/CT in follow-up examinations

Region based agreement (%; kappa value) of DWI-MRI with 18F-FDG PET/CT after completion of chemotherapy for treatment response assessment

Time frame: 2 weeks after the 4th cycle of chemotherapy

Secondary Outcomes

Overall Survival

Time frame: 12 months

Progression Free Survival

Time frame: 6 months

Central Contacts

Chengcheng Liao, MD

CONTACT

+8615907817794 148804@qq.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.